Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="BOWN, N" or (type exact bookEditor and editor="BOWN, N")

Add to list
- Journal Article
- A1
- open access
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

G Schleiermacher, J Michon, A Ribeiro, G Pierron, V Mosseri, H Rubie, C Munzer, J Bénard, N Auger, V Combaret, et al.

(2011) BRITISH JOURNAL OF CANCER. 105(12). p.1940-1948
Add to list
- Journal Article
- A1
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma

Jo Vandesompele (UGent) , M BAUDIS, Katleen De Preter (UGent) , Nadine Van Roy (UGent) , P AMBROS, N BOWN, C BRINKSCHMIDT, H CHRISTIANSEN, V COMBARET, M LASTOWSKA, et al.

(2005) JOURNAL OF CLINICAL ONCOLOGY. 23(10). p.2280-2299
Add to list
- Journal Article
- A1
Quality assessment of genetic markers used for therapy stratification

IM AMBROS, J BENARD, M BOAVIDA, N BOWN, H CARON, V COMBARET, J COUTURIER, C DARNFORS, O DELATTRE, J FREEMAN-EDWARD, et al.

(2003) JOURNAL OF CLINICAL ONCOLOGY. 21(11). p.2077-2084
Add to list
- Journal Article
- A1
Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma.

M LASTOWSKA, Nadine Van Roy (UGent) , N BOWN, Franki Speleman (UGent) , P ROBERTS, J LUNEC, T STRACHAN, ADJ PEARSON and MS JACKSON

(2001) MEDICAL AND PEDIATRIC ONCOLOGY. 36(1). p.20-23
Add to list
- Journal Article
- A1
Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?

Jo Vandesompele (UGent) , Franki Speleman (UGent) , Nadine Van Roy (UGent) , Genevieve Laureys (UGent) , C BRINKSCHMIDT, H CHRISTIANSEN, F LAMPERT, M LASTOWSKA, N BOWN, A PEARSON, et al.

(2001) MEDICAL AND PEDIATRIC ONCOLOGY. 36(1). p.5-10
Add to list
- Journal Article
- A1
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11Q deletion in tumors lacking MYCN amplification.

D PLANTAZ, Jo Vandesompele (UGent) , Nadine Van Roy (UGent) , M LASTOWSKA, N BOWN, V COMBARET, MC FAVROT, O DELATTRE, J MICHON, J BENARD, et al.

(2001) INTERNATIONAL JOURNAL OF CANCER. 91(5). p.680-686
Add to list
- Journal Article
- A1
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.

N BOWN, S COTTERILL, M LASTOWSKA, S O'NEILL, ADJ PEARSON, D PLANTAZ, M MEDDEB, G DANGLOT, C BRINKSCHMIDT, H CHRISTIANSEN, et al.

(1999) NEW ENGLAND JOURNAL OF MEDICINE. 340(25). p.1954-1961

Academic Bibliography

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma

Quality assessment of genetic markers used for therapy stratification

Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma.

Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?

Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11Q deletion in tumors lacking MYCN amplification.

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.

Contents

Support

Contact